Hospital of Chengdu University of Traditional Chinese Medicine,China
Yi-Feng Ren is a dedicated medical professional specializing in oncology and clinical medicine. With a robust educational background, including a Master’s degree from Henan University and academic exchange experience at Tokyo University, he is passionate about advancing cancer research and treatment methodologies.
Profile
Education 🎓
Yi-Feng Ren completed his Bachelor’s degree in Clinical Medicine at Chongqing Medical University in June 2017. He then pursued a Master’s degree in Clinical Medicine at Henan University, graduating in June 2020. He further enriched his academic experience with an exchange program at the Department of Medicine, Tokyo University, Japan, from July to September 2019. Currently, he is advancing his studies at Chengdu University of TCM in Oncology.
Experience 🏥
Ren has extensive experience in clinical and translational research, focusing on lung cancer and microbiota interactions. His contributions to the field include roles as a medical practitioner and researcher, alongside active participation in editorial boards of esteemed medical journals.
Research Interests 🔬
Role of Oral Microbiota: Investigating its impact on lung cancer prediction.
Tumor Metastasis Mechanisms: Understanding the biological processes involved in tumor spread.
Patient-Derived Organoids: Exploring clinical applications of organoids for personalized cancer treatment.
Innovative Diagnostics: Developing new approaches for cancer diagnostics.
Therapeutics Development: Advancing treatment methodologies in oncology.
Awards 🏆
Yi-Feng Ren has received various accolades for his contributions to medical research and practice, recognizing his commitment to improving patient care and advancing medical knowledge.
Selected Publications 📚
CXCL9+TAMs and TREM2+TAMs are involved in the invasion and metastasis of ground-glass and part-solid nodules in lung adenocarcinoma. Mol Cancer, 2024.
Oral microbiota as a biomarker for predicting the risk of malignancy in indeterminate pulmonary nodules: a prospective multicenter study. Int J Surg, 2025.
Mechanisms underlying the effects, and clinical applications, of oral microbiota in lung cancer: current challenges and prospects. Crit Rev Microbiol, 2023.
Patient-derived organoids of lung cancer based on organoids-on-a-chip: enhancing clinical and translational applications. Front Bioeng Biotechnol, 2023.
Saliva-microbiome-derived signatures: Expected to become a potential biomarker for pulmonary nodules (MCEPN-1). BMC Microbiol, 2024